Description

With the growing need for better therapeutics, and the current patent cliff that is underway, therapies such as monoclonal antibodies, recombinant protein therapeutics and even vaccines for a whole host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics. However, due to issues with low yields, poor quality and high costs, novel approaches and novel expression systems are currently being discovered.

Mammalian expression systems are the most rapidly growing segment across all expression systems, and their utility has now been advanced with the capability to integrate more technologies together such as genome editing technologies and genetic manipulation technologies. Mammalian expression systems are mostly developed using Chinese Hamster Ovary (CHO) cells and HEK-293 (Human Embryonic Kidney) cells. There have been no significant changes with respect to the cell-types used. Developments have been incremental, with emphasis on production efficiency, yield, DNA vectors used for cell transfection, and the breadth of recombinant products derived from the expression system.

This research service brings out the emerging trends in mammalian cell culture systems on a global scale, through a detailed description of:
The technology capability and value chain; analysis of global technology trends.
An impact analysis of major drivers, restraints, and challenges influencing the growth of cell banks by timeframes.
An assessment of technology adoption and development, by region, demand side analysis, and recommendations for technology/product/services developers.
An evaluation of scenario modelling and emerging opportunities in mammalian cell culture systems , technology management strategies and technology application roadmap.
A list of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.